{"id":740062,"date":"2023-03-14T16:37:58","date_gmt":"2023-03-14T20:37:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/"},"modified":"2023-03-14T16:37:58","modified_gmt":"2023-03-14T20:37:58","slug":"tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/","title":{"rendered":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting"},"content":{"rendered":"
\n

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1<\/sup> therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR\u237a antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator.<\/p>\n

Poster presentation details:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nLipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Session Category:<\/strong>\n <\/td>\nClinical Research Excluding Trials<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nBiomarkers of Therapeutic Benefit 2<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nMonday, April 17, 2023 9:00 a.m. – 12:30 p.m. ET<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nPoster Section 39<\/td>\n<\/tr>\n
\n Abstract Number:<\/strong>\n <\/td>\n2130<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nGeneration of novel potent human TREX1 inhibitors facilitated by crystallography<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Session Category:<\/strong>\n <\/td>\nExperimental and Molecular Therapeutics<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nNovel Antitumor Agents 3<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nMonday, April 17, 2023 9:00 a.m. – 12:30 p.m. ET<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nPoster Section 17<\/td>\n<\/tr>\n
\n Abstract Number:<\/strong>\n <\/td>\n1636<\/td>\n<\/tr>\n<\/table>\n

___________________________<\/p>\n

\n 1<\/sup> If approved by the FDA<\/p>\n

Abstracts are available for viewing via the AACR Online Itinerary Planner located here, https:\/\/www.abstractsonline.com\/pp8\/#!\/10828<\/a>.<\/p>\n

\n About Tempest Therapeutics <\/strong>\n <\/p>\n

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company\u2019s two novel clinical programs TPST-1120 and TPST-1495, target of PPAR\u03b1 and EP2\/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS\/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company\u2019s website at www.tempesttx.com<\/a>.<\/p>\n

\n Investor Contacts:<\/strong>
\n
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com<\/u><\/a><\/p>\n

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR\u237a antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator. Poster presentation details: Title: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha \u00a0 \u00a0 Session Category: Clinical Research Excluding Trials Session Title: Biomarkers of … <\/p>\n

Continue reading “Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740062","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR\u237a antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator. Poster presentation details: Title: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha \u00a0 \u00a0 Session Category: Clinical Research Excluding Trials Session Title: Biomarkers of … Continue reading "Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T20:37:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting\",\"datePublished\":\"2023-03-14T20:37:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/\",\"name\":\"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=\",\"datePublished\":\"2023-03-14T20:37:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk","og_description":"BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR\u237a antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator. Poster presentation details: Title: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha \u00a0 \u00a0 Session Category: Clinical Research Excluding Trials Session Title: Biomarkers of … Continue reading \"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T20:37:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting","datePublished":"2023-03-14T20:37:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/","name":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=","datePublished":"2023-03-14T20:37:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI4MSM1NDYxODQ3IzIxODk5MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740062"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}